Physician profile
William Sharfman
NPI 1760413652
$112,023.61
in general payments reported to CMS, 2019-2025
18 companies · $20.86 in 2025
The $20.86 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $13K · 2021: $19K · 2022: $23K · 2023: $17K · 2024: $18.96 · 2025: $20.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $2,147 · Consulting Fee: $600 · Food and Beverage: $39.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,469.00 |
| Travel and Lodging | $2,146.69 |
| Consulting Fee | $600.00 |
| Food and Beverage | $39.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $73,701.38 | 2019-2024 | Opdualag |
| Merck Sharp & Dohme LLC | $22,696.61 | 2019-2023 | Keytruda |
| Genzyme Corporation | $7,910.15 | 2020-2021 | |
| Array Biopharma INC | $6,747.96 | 2019-2021 | |
| Emd Serono, INC. | $600.00 | 2021 | |
| Asd Specialty Healthcare, LLC | $217.72 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.12 | 2022 | |
| Gilead Sciences, INC. | $20.86 | 2025 | Trodelvy |
| Sobi, INC | $20.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.92 | 2019 | |
| Amgen INC. | $17.58 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.77 | 2019 | |
| Alkermes, INC. | $15.60 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $15.34 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sharfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.